Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : TFC-1326
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Sirona Biochem Initiates GlycoProteMim Trademark for Anti-Aging Molecule TFC-1326
Details : GlycoProteMim (TFC-1326) is Sirona’s lead anti-aging compound, a topical cream small molecule drug candidate, with potential to reverse the effects of aging on facial skin, restoring lost volume and reducing fine wrinkles.
Brand Name : GlycoProteMim
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 11, 2023
Lead Product(s) : TFC-1326
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : TFC-1326
Therapeutic Area : Dermatology
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Sirona Biochem Announces Exceptional Clinical Trial Results for Anti-Aging Compound TFC-1326
Details : TFC-1326 is Sirona’s lead anti-aging compound, will soon enter a clinical trial designed to assess its potential to reverse the effects of aging on facial skin, restoring lost volume and reducing fine wrinkles.
Brand Name : TFC-1326
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 25, 2023
Lead Product(s) : TFC-1326
Therapeutic Area : Dermatology
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Sirona Biochem Receives Antiviral Testing Results
Details : The ICGEB has successfully screened a library of 20 compounds produced at Sirona’s subsidiary TFChem as potential inhibitors of SARS-CoV-2 using specialized assays developed at the centre.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 27, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : TFC-1326
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Sirona Biochem Announces Start of Clinical Trial for Anti-Aging Compound TFC-1326
Details : The formulation is a cream base with TFC-1326 at a concentration of 1% and no other active ingredients. The trial is designed to assess the compound’s efficacy in reversing aging facial skin, including restoring lost volume (plumping) and reducing fine...
Brand Name : TFC-1326
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 08, 2022
Lead Product(s) : TFC-1326
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : TFC-039
Therapeutic Area : Endocrinology
Study Phase : Preclinical
Sponsor : Wanbang Biopharmaceuticals
Deal Size : Undisclosed
Deal Type : Partnership
Sirona Biochem Signs International Partnership Agreement with Wanbang Biopharmaceuticals
Details : Under the agreement, Wanbang obtained the rights to develop the SGLT2 inhibitor, TFC-039 as a diabetes treatment in China and Sirona retained the global rights. SGLT2 inhibitors provide an opportunity to treat inflicted animals with an oral medication.
Brand Name : TFC-039
Molecule Type : Large molecule
Upfront Cash : Undisclosed
November 23, 2022
Lead Product(s) : TFC-039
Therapeutic Area : Endocrinology
Highest Development Status : Preclinical
Sponsor : Wanbang Biopharmaceuticals
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : TFC-1326
Therapeutic Area : Dermatology
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Sirona Biochem Reports Positive Results in Safety Study for Anti-Aging Compound TFC-1326
Details : TFC-1326 1% in formulation is a non-irritant and non-sensitizer, a claim recognized in the industry based on these results and accepted by global regulatory bodies.
Brand Name : TFC-1326
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 16, 2022
Lead Product(s) : TFC-1326
Therapeutic Area : Dermatology
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Antiviral Therapeutics
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Discovery
Sponsor : International Centre for Genetic Engineering and Biotechnology
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Scientists at ICGEB will test the potential antivirals against SARS-CoV-2 (COVID-19) using specialized assays developed at the centre.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
November 10, 2022
Lead Product(s) : Antiviral Therapeutics
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Discovery
Sponsor : International Centre for Genetic Engineering and Biotechnology
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : TFC-1326
Therapeutic Area : Dermatology
Study Phase : Preclinical
Recipient : WuXi AppTec
Deal Size : Undisclosed
Deal Type : Agreement
Details : TFC-1326 has the potential to replace or supplement dermal filler injections to treat the static wrinkles. TFC-1326 with its unique mechanism of action is revolutionary in the aesthetic skin care space.
Brand Name : TFC-1326
Molecule Type : Small molecule
Upfront Cash : Undisclosed
June 22, 2022
Lead Product(s) : TFC-1326
Therapeutic Area : Dermatology
Highest Development Status : Preclinical
Recipient : WuXi AppTec
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Difluorocyclohexyloxyphenol
Therapeutic Area : Dermatology
Study Phase : Undisclosed
Sponsor : Allergan Aesthetics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Sirona Biochem Announces Exclusive Global Licensing Agreement with Allergan Aesthetics
Details : Under Licensing agreement with Sirona, pursuant to which Allergan Aesthetics will develop and commercialize topical skin care treatments based on active ingredients derived from certain of Sirona’s patents for TFC-1067 (Difluorocyclohexyloxyphenol) and...
Brand Name : TFC-1067
Molecule Type : Small molecule
Upfront Cash : Undisclosed
June 13, 2022
Lead Product(s) : Difluorocyclohexyloxyphenol
Therapeutic Area : Dermatology
Highest Development Status : Undisclosed
Sponsor : Allergan Aesthetics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Difluorocyclohexyloxyphenol
Therapeutic Area : Dermatology
Study Phase : Undisclosed
Sponsor : RODAN & FIELDS LLC
Deal Size : Undisclosed
Deal Type : Termination
Sirona Biochem Announces the Termination of Supply Agreement with Rodan + Fields
Details : Under the terms of the agreement, Sirona will manufacture and supply TFC-1067 (difluorocyclohexyloxyphenol), a novel, new skin brightening ingredient, for use by Rodan + Fields on a non-exclusive basis and Rodan + Fields will launch a new product incorpo...
Brand Name : TFC-1067
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 16, 2022
Lead Product(s) : Difluorocyclohexyloxyphenol
Therapeutic Area : Dermatology
Highest Development Status : Undisclosed
Sponsor : RODAN & FIELDS LLC
Deal Size : Undisclosed
Deal Type : Termination
LOOKING FOR A SUPPLIER?